Login / Signup

Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science.

Joseph E CruzTania AhujaMary Barna Bridgeman
Published in: The Annals of pharmacotherapy (2018)
The SGLT2 inhibitors represents a class of medications that reduce glucose levels via a novel and complementary mechanism. Emerging evidence suggests a plausible explanation for the observed reduction in adverse renal and CV outcomes in recent clinical trials. Questions remain whether these agents reduce renal disease risk greater than achievement of the same glycemic goals as other antidiabetics and whether CV and renal benefits are reproducible in high-risk patients with chronic kidney disease.
Keyphrases
  • clinical trial
  • type diabetes
  • public health
  • heart failure
  • randomized controlled trial
  • emergency department
  • blood pressure
  • atrial fibrillation
  • glycemic control
  • skeletal muscle